Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

Taisho Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: PF-04802540

Study type: Interventional

Funder types: Industry

Identifiers

NCT00756743

B0911002

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.

Full description

Evaluation of safety and pharmacokinetics

Enrollment: 40 patients

Sex: All

Ages: 21 to 54 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males or females of non-childbearing capacity aged 21 to 55 years inclusive at screening.
• Body mass index in the range of 18 to 30 kg/m2 and body weight>45 kg.
• Healthy as determined by the investigator on the basis of screening evaluation.

Exclusion criteria

• Use of prescription or nonprescription drugs
• Any condition possibly affecting drug absorption

Trial design

40 participants in 2 patient groups, including a placebo group

PF-04802540

Experimental group

Treatment:

Drug: PF-04802540

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo